Medical Cannabinoids for Cancer Cachexia: A Systematic Review and Meta-Analysis.

Objectives. Cancer cachexia (CCA) is an intractable and ineffective metabolic syndrome that attacks 50–80% of cancer patients. It reduces patient's life quality, affects the efficacy of treatment, and then increases their mortality; however, there are no established therapeutic strategies for CCA in...

Descripción completa

Detalles Bibliográficos
Publicado en:BioMed Research International pp. 1 - 7
Autores principales: Wang, Jing, Wang, Yanling, Tong, Mengting, Pan, Hongming, Li, Da
Formato: meta analysis research systematic review tables/charts Journal Article
Publicado: Wiley-Blackwell 6/23/2019
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=137123830&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 137123830
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        23146133
        FT2T
      jtl: BioMed Research International
      issn: 23146133
      maglogo: N
    pubinfo:
      dt: 6/23/2019
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        137123830
        137123830
        137123830
        10.1155/2019/2864384
        137123830
      ppf: 1
      ppct: 6
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Medical Cannabinoids for Cancer Cachexia: A Systematic Review and Meta-Analysis.
      aug:
        au:
          Wang, Jing
          Wang, Yanling
          Tong, Mengting
          Pan, Hongming
          Li, Da
        affil: Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
      sug:
        subj:
          Medical Marijuana Therapeutic Use
          Neoplasms Complications
          Cachexia Etiology
          Cachexia Drug Therapy
          Human
          Systematic Review
          Meta Analysis
          Treatment Outcomes
          Cochrane Library
          Medline
          Embase
          PubMed
          Appetite
          Confidence Intervals
          Adverse Drug Event
          Quality of Life
      ab: Objectives. Cancer cachexia (CCA) is an intractable and ineffective metabolic syndrome that attacks 50–80% of cancer patients. It reduces patient's life quality, affects the efficacy of treatment, and then increases their mortality; however, there are no established therapeutic strategies for CCA in the world. In this study, we assess the positive and negative effects of cannabinoid in the treatment of CCA. Methods. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, Web of Science, and PubMed up to December 2017. Results. Of the 256 screened studies, three studies with a total of 592 participants were included. Compared with placebo, cannabinoid increased the appetite (MD 0.27, 95% CI -0.51 to 1.04; n= 3) but failed to improve the overall quality of life (QOL; MD -12.39, 95% CI [-24.21 to -0.57; n = 2), and a total of 441 patients had 607 adverse events (AEs; 496 in the cannabinoid group and 111 in the placebo group). Conclusions. Our analysis showed cannabinoid is effective in increasing appetite in cancer patients. However, it declines the quality of life, which may be due to the side effects of cannabinoid.
      pubtype: Academic Journal
      doctype:
        meta analysis
        research
        systematic review
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N